U.K.-based biotech Alchemab on Tuesday announced a licensing agreement with Eli Lilly (NYSE:LLY) to jointly develop ATLX-1282, an early-stage therapeutic candidate targeting amyotrophic lateral ...

U K-based Alchemab has secured a licensing agreement worth up to $415m with Eli Lilly for ATLX-1282, its investigational antibody therapy targeting amyotrophic lateral sclerosis (ALS) and other ...

Eli Lilly is licensing rights to a Phase 1-ready antibody that startup Alchemab developed for amyotrophic lateral sclerosis and other neurodegenerative disorders. Lilly’s pipeline has ALS drug ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing its first drug asset from the deal. Lilly will pay up to $415 million in ...

Eli Lilly has added another candidate to a growing pipeline of amyotrophic lateral sclerosis (ALS) therapies, tapping UK start-up Alchemab for an antibody currently being prepared for clinical ...

Shares of Verve Therapeutics skyrocketed 75% Tuesday morning after Eli Lilly announced that it would acquire the gene-editing ...

Eli Lilly has entered into an exclusive licensing agreement with Alchemab Therapeutics for ATLX-1282, ... (ALS) and other neurodegenerative conditions. Under the terms of the agreement, Lilly will pay ...

Eli Lilly will be licensing Alchemab Therapeutics’ preclinical programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in a deal worth up to $415m. The agreement, ...

- New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and mechanism ...

UK-based Alchemab has secured a licensing agreement worth up to $415m with Eli Lilly for ATLX-1282, its investigational antibody therapy targeting amyotrophic lateral sclerosis (ALS) and other ...

Alchemab's Chief Executive Officer, Jane Osbourn, commented: "As the first programme from our highly novel platform, this is a landmark transaction for Alchemab. With Lilly's deep expertise in ...

UK-based Alchemab has secured a licensing agreement worth up to $415m with Eli Lilly for ATLX-1282, its investigational antibody therapy targeting amyotrophic lateral sclerosis (ALS) and other ...